ibuprofen lysine
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 23
Of
23
Go to page
1
June 18, 2025
Ibuprofen lysine salt complexed with β-cyclodextrin oral suspension: an innovative pediatric formulation with clinical advantages.
(PubMed, Minerva Pediatr (Torino))
- "Based on this evidence, ILS-β-CD may represent a beneficial option for managing fever and pain in children and adolescents. This formulation may provide a rapid onset of action and prolonged concentrations, assuring adequate therapeutic concentrations, optimal tolerability, and a valuable safety profile."
Journal • Pain • Pediatrics
April 02, 2025
Caffeine and/or Ibuprofen Effects on Biomarkers of Alveolarization and Microvascular Maturation in Neonatal Rat Lungs in the Saccular Stage of Development.
(PAS 2025)
- "Caffeine citrate (Caff) and Ibuprofen lysine (Ibu) are used for apnea and closure of a symptomatic PDA, respectively. Hx and IH resulted in significant damage in the Sal groups with reductions in secondary crest formation (Hx:16.2±1.2; IH: 12.5±1.5 vs. RA: 22.1±1.8, p< 0.01). Radial alveolar counts were reduced and medial wall thickness (μm) increased in Hx (3.2±0.17 and 0.34±0.02, respectively, p< 0.01) and IH (3.2±0.21 and 0.35±0.02, respectively, p< 0.01) vs."
Preclinical • Cardiovascular • Hematological Disorders • Hypertension • CDKN1A • MMP2 • MMP9
February 12, 2025
Co-administration of Acetaminophen with Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
(clinicaltrials.gov)
- P2 | N=310 | Recruiting | Sponsor: Mount Sinai Hospital, Canada | Trial completion date: Dec 2026 ➔ Apr 2027 | Trial primary completion date: May 2026 ➔ Jan 2027
Trial completion date • Trial primary completion date
September 11, 2024
Damage to gut lining from ulcers, ibuprofen may increase Parkinson’s risk
(Medical News Today)
- "Daniel Truong, MD...explained to Medical News Today how this study adds further evidence for a link: 'The GI tract is known to produce alpha-synuclein, a protein that plays a key role in Parkinson's. When the gut lining is damaged, it may lead to chronic inflammation or an impaired ability to clear harmful proteins, which could trigger the misfolding of alpha-synuclein.'"
Media quote
June 21, 2024
CANRxPDA: Canadian National PDA Treatment Study
(clinicaltrials.gov)
- P=N/A | N=1663 | Completed | Sponsor: IWK Health Centre | Recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ Dec 2023
HEOR • Trial completion • Trial completion date
March 29, 2024
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
(PubMed, Eur J Clin Pharmacol)
- "Most secondary test drugs, except aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine, were physicochemically compatible with caffeine citrate injection. Caffeine base injection was physicochemically compatible with all 43 test drugs tested."
Journal • Critical care
March 28, 2024
The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings.
(PubMed, Pharmaceutics)
- "Sildenafil 600 mcg/mL was compatible with lower, clinically relevant concentrations of calcium gluconate, heparin and hydrocortisone. Aciclovir, amoxicillin, ampicillin, ibuprofen lysine, indometacin, phenobarbitone and rifampicin were incompatible with sildenafil 600 mcg/mL, however these IV medications were compatible with sildenafil 60 mcg/mL. Sildenafil 600 mcg/mL and 60 mcg/mL were incompatible with amphotericin, flucloxacillin, furosemide, ibuprofen, meropenem and sodium bicarbonate. Sildenafil compatibility with commonly used syringe filters was also investigated. Sildenafil solution was compatible with nylon syringe filters, however, absorption/adsorption loss occurred with polyethersulfone and cellulose ester filters."
Journal • Cardiovascular • Critical care • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
March 09, 2024
Early versus late caffeine and/or non-steroidal anti-inflammatory drugs (NSAIDS) for prevention of intermittent hypoxia-induced neuroinflammation in the neonatal rat.
(PubMed, Int J Dev Neurosci)
- "For early treatment, the pups were administered: 1) daily caffeine (Caff) citrate (Cafcit, 20 mg/kg IP loading on P0, followed by 5 mg/kg from P1-P14); 2) ketorolac (Keto) topical ocular solution in both eyes from P0 to P14; 3) ibuprofen (Ibu, Neoprofen, 10 mg/kg loading dose on P0 followed by 5 mg/kg/day on P1 and P2); 4) Caff+Keto co-treatment; 5) Caff+Ibu co-treatment; or 6) equivalent volume saline (Sal). Early treatment with Caff alone or in combination with NSAIDs conferred better neuroprotection against IH-induced damage than late treatment. Early postnatal treatment during a critical time of brain development, may be preferable for the prevention of IH-induced brain injury in preterm infants."
Journal • Preclinical • CNS Disorders • Hematological Disorders • Inflammation • Rheumatoid Arthritis • Vascular Neurology • CDKN1A
February 01, 2024
Efficacy of Ibuprofen Lysine on First-Trimester AbortionRelated Pain and Hemorrhage: A Randomized TripleBlinded Clinical Trial.
(PubMed, Arch Iran Med)
- "The use of NSAIDs (ibuprofen lysine) is a good pharmacological analgesic option for relieving medical abortionrelated pain and hemorrhage."
Journal • Hematological Disorders • Pain
August 30, 2023
Investigating the Effect of Basic Amino Acids and Glucosamine on the Solubility of Ibuprofen and Piroxicam.
(PubMed, Adv Pharm Bull)
- "The solubility of PXM in accompany of GlucN in water did not change significantly while in citrate buffer solubility enhanced specially at pH 6. Overall, GlucN in citrate buffer and ARG in phosphate buffer could be introduced as the most suitable media for IBU and PXM solubility improvement, respectively."
Journal
April 04, 2023
CANRxPDA: Canadian National PDA Treatment Study
(clinicaltrials.gov)
- P=N/A | N=1350 | Recruiting | Sponsor: IWK Health Centre | Trial primary completion date: Apr 2023 ➔ Aug 2023
HEOR • Trial primary completion date
April 04, 2023
"Is there a difference b/w IV ibuprofen lysine and THAM in terms of PDA closure efficacy? Our @DalMedSchool Pediatric resident @telizart presents the results of our latest NMA at the @DalhousieU Pediatric Trainee Research Day @IWKHealth @EBNEO @neo_twiter @halifaxtim @rmnparker"
(@souvik_neo)
Clinical • Pediatrics
February 01, 2023
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
(clinicaltrials.gov)
- P2 | N=310 | Recruiting | Sponsor: Mount Sinai Hospital, Canada | Not yet recruiting ➔ Recruiting
Enrollment open
January 28, 2023
Efficacy of Different Ibuprofen Formulations with Two Prescription Methods on Post Endodontic Pain of Teeth with Irreversible Pulpitis: A Randomized Clinical Trial.
(PubMed, Iran Endod J)
- "This study aimed to compare the effect of two non-steroidal anti-inflammatory drugs (NSAIDs); ibuprofen and ibuprofen lysine with two methods of prescription on pain after single-visit root canal treatment of first and second mandibular molar teeth with irreversible pulpitis...Additionally, there was no significant difference in the degree of pain between the on-demand and regular groups, despite the fact that patients in the on-demand group used less medications. Due to the multiple negative effects of NSAIDs, it would be wise to prescribe ibuprofen on demand."
Clinical • Journal • Dental Disorders • Pain
September 01, 2022
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
(clinicaltrials.gov)
- P2 | N=310 | Not yet recruiting | Sponsor: Mount Sinai Hospital, Canada | Initiation date: Jul 2022 ➔ Oct 2022
Trial initiation date
April 22, 2022
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
(clinicaltrials.gov)
- P2 | N=310 | Not yet recruiting | Sponsor: Mount Sinai Hospital, Canada
New P2 trial
November 17, 2021
Benzannulation and Hydrocarboxylation Methods for the Synthesis of a Neopentylene-Fused Analogue of Ibuprofen.
(PubMed, ACS Omega)
- "Here is reported a synthetic approach to one of the few non-natural product-based target compounds from medicinal chemistry that includes a neopentylene ring fusion: an analogue of ibuprofen referred to herein as "neoprofen". The approach features ring-opening fragmentation reactions of dimedone derivatives coupled with transition metal-catalyzed benzannulation and hydrocarboxylation methods."
Journal
April 23, 2021
Comparative taste-masking evaluation of microencapsulated bitter drugs using Smartseal 30D and ReadyMix for paediatric dosage forms.
(PubMed, AAPS PharmSciTech)
- "The aim of the study was to evaluate the taste masking effectiveness of Smartseal 30D and ReadyMix on a range of bitter drug substances such as diphenhydramine HCl (DPD), ibuprofen lysine (IBU-LS), and phenylephrine HCl (PPH) for the development of paediatric dosage forms...Spray drying of drug formulations was optimized in terms of percent yield and encapsulation efficiency followed by physicochemical characterization in order to identify the drugs' physical state in the polymer microparticles. The in vivo taste masking efficiency was evaluated using human test panel and showed noticeable reduction of drug's bitterness at all loadings in comparison to the bulk substances."
Journal • Pediatrics
December 21, 2020
CANRxPDA: Canadian National PDA Treatment Study
(clinicaltrials.gov)
- P=N/A; N=1350; Recruiting; Sponsor: IWK Health Centre; Not yet recruiting ➔ Recruiting; Initiation date: Apr 2020 ➔ Jan 2020
Clinical • Enrollment open • HEOR • Trial initiation date
September 10, 2020
"Ibuprofen as 1st line Safety of NeoProfen for PDA https://t.co/nOY93CD03Y Feeding during ibuprofen https://t.co/Z4B9JiZpoz"
(@toanped)
Clinical
March 12, 2017
"Not using much Cangrelor. If IV antiplt is needed, I go with bolus 2b3a or bolus + short infusion."
- SVRaoMD
Biosimilar
January 22, 2015
The Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: State University of New York - Downstate Medical Center
New P2 trial • Biosimilar • Oncology
February 17, 2019
Improved synthesis of “neoprofen”, a rigidified analogue of ibuprofen
(ACS-Sp 2019)
- "Due to these factors, nonaflates have proven to be both convenient and efficient relative to triflates. The integration of these observations into other synthetic efforts is expected to advance chemical synthesis and impact future medicinal chemistry efforts."
1 to 23
Of
23
Go to page
1